Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 130.42M | 110.49M | 168.34M | 164.58M | 275.11M | 122.69M |
Gross Profit | 127.40M | 98.39M | -85.26M | 155.78M | 267.62M | -47.11M |
EBITDA | -158.48M | -186.17M | -125.87M | -72.16M | 51.26M | -71.00M |
Net Income | -213.00M | -232.62M | -126.09M | -55.18M | 82.63M | -63.54M |
Balance Sheet | ||||||
Total Assets | 904.69M | 951.95M | 952.69M | 846.27M | 838.21M | 703.24M |
Cash, Cash Equivalents and Short-Term Investments | 469.57M | 497.77M | 593.73M | 623.06M | 334.11M | 603.00M |
Total Debt | 67.82M | 231.95M | 83.43M | 59.63M | 33.97M | 11.63M |
Total Liabilities | 264.81M | 277.92M | 283.56M | 118.77M | 104.71M | 130.80M |
Stockholders Equity | 639.87M | 677.61M | 668.80M | 727.50M | 733.50M | 572.44M |
Cash Flow | ||||||
Free Cash Flow | -173.04M | -208.28M | 63.86M | -18.92M | -32.83M | -18.77M |
Operating Cash Flow | -163.15M | -202.19M | 85.11M | 24.48M | -16.85M | -5.00M |
Investing Cash Flow | -26.52M | -7.87M | -111.06M | -119.72M | -46.25M | 100.19M |
Financing Cash Flow | 198.22M | 197.15M | 26.18M | 5.70M | 43.04M | 18.04M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
62 Neutral | $921.16M | ― | -40.13% | ― | ― | -3.08% | |
60 Neutral | HK$15.58B | 5.65 | -7.43% | 4.32% | 11.60% | -21.06% | |
59 Neutral | $1.11B | ― | -57.92% | ― | -13.37% | 2.57% | |
54 Neutral | $760.74M | ― | 222.83% | ― | 29.88% | 35.11% | |
50 Neutral | $580.28M | ― | -35.41% | ― | ― | ― | |
46 Neutral | $599.26M | ― | -33.48% | ― | -25.88% | -29.16% | |
40 Underperform | $312.44M | ― | -60.45% | ― | ― | 6.99% |
On June 12, 2025, Xencor, Inc. held its Annual Meeting of Stockholders, where 94.68% of the company’s shares were represented. During the meeting, stockholders elected eight directors, ratified KPMG LLP as the independent accounting firm, approved an amendment to increase shares in the Equity Incentive Plan by 3,000,000, and supported the executive compensation plan.
The most recent analyst rating on (XNCR) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Xencor stock, see the XNCR Stock Forecast page.
On May 5, 2025, Xencor announced the resignation of Nancy Valente as Executive Vice President and Chief Development Officer, effective June 6, 2025, with plans for her to continue as a senior advisor. The company reported its first-quarter 2025 financial results, highlighting a net loss reduction compared to the previous year and increased revenues primarily from non-cash royalty and milestone payments. Xencor is advancing its XmAb942 antibody for ulcerative colitis into a Phase 2b study and is preparing a bispecific antibody candidate for Phase 1 trials in 2026. The company expects to maintain significant cash reserves to fund operations into 2028.
On April 29, 2025, Xencor announced interim results from its Phase 1 dose-escalation study of XmAb942 (Xtend™ TL1A), highlighting its potential for treating inflammatory bowel disease (IBD). The company also shared preclinical data from its XmAb TL1A x IL23p19 program, suggesting promising clinical timelines. These developments underscore Xencor’s strategic focus on advancing its XmAb drug candidates, potentially strengthening its position in the biotechnology sector and offering new therapeutic options for stakeholders.